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Abstract
Background: The rs7903146 and rs12255372 variants of TCF7L2 have been strongly associated
with type 2 diabetes (T2D) risk in most populations studied to date. Meta-analysis of 27 different
studies has resulted in a global OR of 1.46 [1.42–1.51] (rs7903146 variant). Thus far, despite a high
incidence of T2D, the role of this variant in Arabs has not been established.
Methods: We performed a case-control association study using 522 Saudi T2D patients (WHO
criteria), and 346 controls (age > 60; fasting plasma glucose < 7 mmol/L). Genotyping was
performed by pyrosequencing. Statistical analyses were performed using SPSS version 13.0 for
Windows (SPSS, Chicago, IL, USA).
Results: For rs7903146, the T allele frequency of the cases (0.415) was not different from that
observed in the controls (0.405). The crude odds ratio (OR) was 1.04 with a 95% CI of 0.86–1.27
(P = 0.675). For rs12255372, the T allele frequency of the cases (0.368) was not different from that
observed in the controls (0.355). Retrospective power calculations based upon an OR of 1.46
reported in a comprehensive meta-analysis of TCF7L2 risk, indicated this study was sufficiently
powered (96.92%; α = 0.05) to detect an effect of similar magnitude to that reported for
rs7903146.
Conclusion: Our study is consistent with weak or no association of T2D in Arabs with the two
TCF7L2 variants, however it cannot rule out an effect of other SNPs in this gene. Future studies in
this population are required to confirm our findings and may indicate the presence of yet to be
defined genetic risk factors for T2D.
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Background
Type 2 diabetes (T2D) is one of the most common non
infectious diseases globally and is a health-care problem
worldwide affecting both industrial and developing
nations [1]. A clear link has been made between genetic
defects and the less common monogenic forms of diabe-
tes, such as maturity onset diabetes of the young (MODY)
and neonatal diabetes [2,3]. Conversely, the genetics
underlying type 2 diabetes is multifactorial and complex
in nature[4]. Multiple genetic and environmental factors
contribute to individual risk of developing type 2 diabe-
tes. Some have only a marginal and modest effect when
considered individually, and the combination of these
factors is responsible for disease risk. Most genetic studies
that have addressed these factors have not provided repro-
ducible conclusions [5]. Studies which investigated the
P12A variant in PPARG and E23K in KCNJ11 have pro-
vided only a modest disease risk and hence presented little
explanation to the disease etiology [6,7]. More recently,
researchers at Decode Genetics reported strong associa-
tion between variants in a novel susceptibility gene called
TCF7L2 and type 2 diabetes in Icelandic diabetic patients
[8]. TCF7L2 encodes the transcription factor 7-like 2 [9].
The overexpression of this gene in human pancreatic β
cells was shown to associate with impaired insulin secre-
tion both in vivo and in vitro [10]. This gene received
attention from many research groups following this
report, and similar studies were replicated in samples
from several populations. Many studies have confirmed
the original findings. Substantial association has been
confirmed between variants in TCF7L2 and type 2 diabe-
tes among broad ethnic backgrounds, including for exam-
ple populations of UK [11], Dutch [12], Amish [13],
Finnish [14], Swedish [15], French [16] and US [17,18],
Indian [19], and Japanese [20] origin. It is noteworthy
that, as in the original report, there was clear evidence of
a gene dosage effect, such that the 10% of individuals with
two copies of the susceptibility allele were at almost twice
the risk of developing type 2 diabetes compared to those
with only one copy [11,21]. Very recently, lack of associa-
tion between variants in TCF7L2 and type 2 diabetes has
been reported in Pima Indians and Chinese diabetics
[22,23]. In another association study performed in Emir-
ati Arabs [24], the authors reported only a marginal asso-
ciation between rs12255372 and type 2 diabetes risk and
no association with rs7903146. We have previously stud-
ied the P12A [25] and E23K [26] variants in a cohort of
T2D subjects of Arabian origin. Our aim in this study was
to replicate the TCF7L2 gene studies in these same sub-
jects. We focused on two of the best studied SNPs in this
gene (rs7903146 and rs12255372) to examine whether
they contribute to the risk of type 2 diabetes in an Arab
population using unrelated subjects and non-diabetic
controls of Saudi origin.
Research design and methods
Subjects
Random unrelated Saudi T2D patients (522) were
recruited through a program for the Genetic Study of
Saudi Diabetes (GSSD). Diagnosis was based upon WHO
criteria (fasting plasma glucose > 7.0 mmol/l, and/or 2 hr
OGTT ≥ 11.1). Their age ranged between 60 and 88 years.
Control subjects (346) were random unrelated ano-
nymised individuals, aged between 60–95 years with a
fasting plasma glucose < 7.0 mmol/l (highly unlikely to
develop T2D). Patient's participation in this study was
with full informed consent based on the principles of the
Declaration of Helsinki and as required by the Institu-
tional Review Boards of King Faisal Specialist Hospital
and Research Center and The University Diabetes Center
at King Saud University.
Blood sample collection and DNA extraction
Peripheral blood was drawn from type 2 diabetes patients
and controls in EDTA anticoagulated tubes. DNA was
extracted from whole blood using the PUREGENE DNA
Isolation Kit (Gentra Systems, Minneapolis, MN, USA) as
recommended by the manufacturer. DNA was quantified
spectrophotometrically prior to use in PCR.
PCR and pyrosequencing
PCR reaction consisted of 2.0 μL Qiagen 10× Buffer con-
taining 15 mM MgCl2 solution (Qiagen, Valencia, CA,
USA), 2 μL of 2.5 mM dNTP (EPICENTER Biotechnolo-
gies, Madison, WI, USA), 1 μL of 5 pmol/μL forward
primer and 1 μL of 5 pmol/μL 5' BIOTINYLATED reverse
primer (Metabion, Germany), 2 μL of 25 ng/μL DNA tem-
plate, 0.2 μL (1 unit) Taq polymerase (Qiagen, Valencia,
CA, USA), and sterile water to 20 μL total reaction vol-
ume. PCR thermal cycling was done on PTC-200 (MJ
Research, Watertown, MA, USA) using the following con-
ditions: "heated lead", 95°C for 15 min; 35 cycles consist-
ing of denaturation at 95°C for 30 s, annealing at 54°C
for 30 s, and extension at 72°C for 30 sec; and final exten-
sion at 72°C for 5 min. PCR primers were designed using
PSQ Assay Design Software (PyroMark™ MD version 1.0,
Biotage, Sweden). Pyrosequencing was performed for
sequence determination and allele designation in a
Biotage PSQ HS 96 System, and data were captured with
PSQ HS 96 SNP software. Pyrosequencing was performed
as described previously [27]. Briefly, the biotinylated PCR
products (20 μL) were immobilized onto streptavidin-
coated Sepharose Dynabeads™ M280-streptavidin (Dynal
A.S., Oslo, Norway). Using Pyrosequencing wash unit,
Single-stranded DNA sequencing template was obtained
by discarding the supernatant after incubation of the
bead-immobilized PCR biotinylated strand in 0.10 M
NaOH for 30 sec. Beads were then treated with 70% etha-
nol, denaturation buffer, wash buffer, and released into a
96 well PSQ sequencing plate containing annealing bufferBMC Medical Genetics 2008, 9:72 http://www.biomedcentral.com/1471-2350/9/72
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and 10 pmol of the appropriate sequencing primer. The
plate was heated at 80°C for 5 min, cooled to 55°C for 4
min, and then allowed to stay at room temperature.
Primed DNA was finally placed in the PSQ™ Pyrosequenc-
ing machine. Pyrosequencing™ substrate and enzymes
were dispensed using the fully automated microtiter plate-
based Pyrosequencing machine. The progress of sequenc-
ing was followed in real time using Pyrosequencing SNP
software http://www.pyrosequencing.com. Genotypes for
96-well plates were generated in 10 min. For quality con-
trol, replicate 96-well plates (one full plate per each SNP)
were included in the analysis and genotyped with 100%
concordance. SNP genotyping success rates also ranged
between 93–98% for the successive runs.
Statistical analysis
Genotype frequencies were tested for Hardy-Weinberg
equilibrium by χ2 analysis. Mean age of cases and controls
was compared by t-test. Multiple logistic regression was
used to study the effect of each allele on the risk of diabe-
tes when adjusting for age and sex. Differences in case and
control groups for allele, genotype and haplotype fre-
quencies were tested for significance using a 95% two-
sided χ2 test. Individuals homozygous for the common
allele were used as reference, to test for association of gen-
otype with T2D using a logistic regression model to calcu-
late Odds ratios (ORs) with 95% confidence intervals
(CIs). Haplotypes of the two SNPs were estimated using
the SAS Genetics statistical software package (SAS Institute
Inc., Cary, NC, USA, 2002). Estimates of linkage disequi-
librium (LD; D'  and  r2) between rs7903146 and
rs12255372 were made using the same package. All statis-
tical analyses were performed using SPSS version 13.0 for
Windows (SPSS, Chicago, IL, USA) unless otherwise indi-
cated.
Results
We conducted a case-control association study compris-
ing 522 T2D patients and 346 controls, both aged above
60 years (Table 1). Both groups were of Saudi ancestry and
representative of an Arab population. The rationale
behind the minimum age selection was to ensure the
absence of silent diabetics within the control group. The
male gender distribution was 58.1% (201) vs 57.5%
(300) among controls and patients respectively, there
being no significant difference in the groups, p = 0.856.
The age range of controls and cases respectively was 60–
95 and 60–88 years. The mean age was 68.6 (± 7.0) and
67.2 (± 6.0) for controls and patients respectively and was
found to be significantly different (p = 0.002) (Table 1).
For rs7903146, the T allele frequency of the cases (0.415)
was not different from that observed in the controls
(0.405) (Table 2). The crude odds ratio (OR) was 1.04
with a 95% CI of 0.86–1.27 (P = 0.675) (Table 2). Retro-
spective power calculations based upon an OR of 1.46
reported in a comprehensive meta-analysis of TCF7L2 risk
[28], indicated this study was sufficiently powered
(96.92%; α = 0.05) to detect an effect of this magnitude or
greater. The CT genotype frequency of the cases was 0.485
compared to 0.468 among the controls, the difference was
not significant when compared to the CC reference geno-
type (OR 1.09, 95% CI 0.81–1.47, P = 0.573). TT geno-
type frequency of both the cases and controls was also
compared to the CC reference genotype and resulted in a
P value of 0.757, and an OR of 1.065 with a 95% CI of
(0.71–1.59). This indicated no significant difference
between the cases and controls with respect to CT and TT
genotypes (Table 2).
For rs12255372, the T allele frequency of the cases
(0.368) was not different from that observed in the con-
trols (0.355) (Table 2). The crude odds ratio (OR) was
1.06 with a 95% CI of 0.86–1.29 (P = 0.601) (Table 2).
The GT genotype frequency of the cases was 0.456 com-
pared to 0.468 among the controls, the difference was not
significant when compared to the GG reference genotype
(OR 0.989, 95% CI 0.74–1.32, P = 0.938). TT genotype
frequency of both the cases and controls was also com-
pared to the GG reference genotype. The statistical analy-
sis resulted in a P value of 0.48, and an OR of 1.17 with a
95% CI of (0.76–1.81). This also indicated no significant
difference between the cases and controls with respect to
rs12255372 GT and TT genotypes (Table 2).
It was noted that the cases and controls differed slightly
with respect to age. Multiple logistic regression analysis
was used to correct for the effect of age and sex on geno-
type (Tables 3 &4). Data showed that, even after adjust-
ment for the joint effects of sex and age, the genotypes
were not significantly associated with T2D.
Table 1: Description of study controls and type 2 diabetes subjects
Subjects Controls (n = 346) Diabetics (n = 522) p-value
BMI (kg/m2) NA 28.9 ± 5.48 -
Male distribution (%) 58.1 (201/346) 57.7 (300/522) 0.856
Mean age (years) 68.6 ± 7.0 67.2 ± 6.0 0.002
Age range (years) 60–95 60–88 -BMC Medical Genetics 2008, 9:72 http://www.biomedcentral.com/1471-2350/9/72
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The allele frequencies for rs7903146 and rs12255372
SNPs in cases and controls were in Hardy-Weinberg equi-
librium and both SNPs were found to be in modest LD
with each other (D' = 0.8, r2 = 0.66). The frequency of the
TT haplotype, which carries the two minor alleles (risk
alleles in other populations) of both SNPs, was not signif-
icantly different in subjects compared to controls (33% vs
30% respectively; p = 0.1373). Differences between cases
and controls for the other haplotypes of rs7903146 (C/T)
and rs12255372 (G/T) were not significantly different
with the exception of the CT haplotype (p = 0.0312).
However, the CT haplotype was only observed in a com-
bined total of 38 individuals from cases and is underpow-
ered for such comparison.
In order to determine whether the at risk variants of
rs7903146 and rs12255372 interacted with body mass
index (BMI) we studied the association between these
alleles and this covariate in 200 T2D cases from this study
for which BMI was available. The mean BMI for this group
of patients was 28.9 ± 5.5. The mean BMI for the C and T
allele of rs7903146 was 28.7 ± 5.4 and 29.1 ± 5.6 respec-
tively (P = 0.508). Similarly the mean BMI for the G and
T alleles of rs12255372 (28.6 ± 5.4 and 29.4 ± 5.7 respec-
tively) were not significantly different (P = 0.190). The
association of BMI with genotypes of rs7903146 and
rs12255372 was also not statistically significant (P =
0.442 and P = 0.078 respectively).
Discussion and conclusion
Variants in TCF7L2 have been strongly associated with
type 2 diabetes risk [28]. In this study, we aimed to
explore the effects of rs7903146 and rs12255372 variants
in an Arab population. Previous reports [11-14,16-19,29]
have suggested a positive association between TCF7L2
variants and T2D. In our case-control study, we found that
rs12255372 and rs7903146 were not associated with T2D
making this the first study to find simultaneously no asso-
ciation between these variants in TCF7L2  and T2D in
Arabs. Several studies from non-European ethnic back-
grounds have reported a positive association between
TCF7L2  variants and T2D. The first, an Indian study,
Table 2: Univariate analysis relating allele and genotype to the risk of diabetes
Subjects Controls Diabetics Odds ratio (95% CI) p-value
SNP genotypes
rs7903146
C allele (%) 412 (59.5) 611(58.5) -
T allele (%) 280(40.5) 433(41.5) 1.04 (0.86–1.27) 0.675
CC genotype (%) 125(36.1) 179(34.3) -
CT genotype (%) 162(46.8) 253(48.5) 1.09 (0.81–1.47) 0.573
TT genotype (%) 59(17.1) 90(17.2) 1.065 (0.71–1.59) 0.757
rs12255372
G allele (%) 446(64.5) 660(63.2)
T allele (%) 246(35.5) 384(36.8) 1.06 (0.86–1.29) 0.601
GG genotype (%) 142(41.0) 211(40.4)
GT genotype (%) 162(46.8) 238(45.6) 0.989 (0.74–1.32) 0.939
TT genotype (%) 42(12.1) 73(14.0) 1.17 (0.76–1.81) 0.48
Table 3: rs7903146 multiple logistic regression to see the effect of genotype on the risk of diabetes after controlling for age and sex
Variables
Odds ratio 95.0% C.I.for Odds ratio P-value
Lower Upper
Sex (female reference) .997 .755 1.315 .982
age .966 .946 .987 .001
rs4903146 .856
CC Reference
CT 1.061 .709 1.587 .774
TT 1.090 .804 1.477 .579BMC Medical Genetics 2008, 9:72 http://www.biomedcentral.com/1471-2350/9/72
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investigated 3 TCF7L2 variants (rs7903146, rs12255372,
and rs4506565) and reported significant association
between all 3 SNPs and T2D [19]. In a Japanese study, 4
TCF7L2  SNPs were explored (rs12255372, rs7903146,
rs7901695 and rs11196205) and all 4 SNPs were found to
be significantly associated with T2D, with rs12255372
showing the strongest association [20]. The third study
was conducted by Cauchi et al. on Moroccans [28]. Signif-
icant association between rs7903146 variant of TCF7L2
and T2D risk in this population was concluded. Addition-
ally, positive association was also reported on Indian
Asians [30,31], Pakistanis [32], and Afro-Caribbeans [31].
More recently, a surprising lack of association between
TCF7L2 variants and type 2 diabetes was independently
reported in three non-European populations including
Chinese [22], Pima Indians [23], and in respect to
rs7903146 in Emirati Arabs [24]. In a systemic meta anal-
ysis conducted by Cauchi et al., the authors reviewed the
association of rs7903146 variant with T2D risk by looking
at 27 original published association studies (including
their own), the authors arrived at a pooled OR of 1.46
[1.42–1.51]. Whilst there is no overlap between the over
all OR and CIs of this meta-analysis and the upper CI of
our study (1.27), however there is an overlap with three
studies included in this meta-analysis [17,31,33]. There-
fore, even though significant association was not indi-
cated by our study, a weak association cannot be ruled out
and justifies a larger replication study in Arabs. Within
T2D patients of this population, BMI was not associated
with allele frequencies for rs12255372 and rs7903146
SNPs. This is consistent with studies performed in other
populations where BMI was essentially similar to that
reported in our study [8,12,17,18].
TCF7L2 variants linked to T2D so far are all intronic, and
there is no clear mechanism so far linking T2D patho-
genicity to this gene. TCF7L2 is widely expressed [16],
however little is known about its biological role and the
predisposition to diabetes. Current evidence suggests the
idea that the predominant effect of TCF7L2 dysfunction
on type 2 diabetes development is mediated through
impairment of insulin secretion [13,14,17,19,21]. A
meta-analysis of 27 different populations confirmed asso-
ciation of rs7903146 with T2D in diverse populations
with a global OR of 1.46 [1.42–1.51] showing a uniform
risk conferred through the effect of TCF7L2. The absence
of heterogeneity among studies was considered indicative
of a universal contribution of this gene to T2D [28].
Whilst TCF7L2 clearly confers yet the strongest and most
widespread association with T2D, our results suggest cau-
tion should be exercised, especially in light of other very
recent reports [22,23] which have also shown that these
two TCF7L2 variants are not associated with type 2 diabe-
tes in other ethnic populations. This is supported further
by the lack of association between type 2 diabetes and
rs7903146 and marginal association with rs12255372 in
Emirati Arabs, a population with a similar incidence of
type 2 diabetes and associated phenotypes[24]. Whilst
marginal association of the T allele of rs12255372 with
type 2 diabetes was reported in this study, cohort size was
small (180 cases and 188 controls) as evidenced by the
broad CI (1.04 – 2.08) for the OR of 1.47. Indeed the CI
overlaps considerably with our findings and highlights
the need for replication studies in a larger cohort of Arabs.
The possibility that other SNPs in TCF7L2 may influence
the disease risk in these populations cannot be excluded.
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Table 4: rs12255372 multiple logistic regression to see the effect of genotype on the risk of diabetes after controlling for age and sex
Odds ratio
95.0% C.I.for Odds ratio
Variable Lower Upper p-value
Sex (female reference) .992 .751 1.309 .953
Age .966 .946 .987 .001
rs12255372 .734
GG (reference)
GT .993 .740 1.331 .960
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